Equities Analysts Issue Forecasts for EW Q4 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Analysts at William Blair raised their Q4 2025 earnings estimates for Edwards Lifesciences in a research report issued on Thursday, December 5th. William Blair analyst M. Andrew now expects that the medical research company will post earnings per share of $0.64 for the quarter, up from their prior forecast of $0.63. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.56 per share.

Several other research analysts have also issued reports on the company. Wells Fargo & Company dropped their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Piper Sandler dropped their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Truist Financial reissued a “hold” rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Robert W. Baird decreased their price objective on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Finally, UBS Group cut their target price on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research note on Tuesday, September 10th. Seventeen research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus target price of $78.35.

Edwards Lifesciences Stock Performance

NYSE EW opened at $73.41 on Monday. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The stock has a market cap of $43.29 billion, a P/E ratio of 10.59, a PEG ratio of 3.52 and a beta of 1.12. The company’s 50-day simple moving average is $68.75 and its 200 day simple moving average is $74.29.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter last year, the company earned $0.59 EPS.

Insider Buying and Selling at Edwards Lifesciences

In related news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,262,521.36. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 35,000 shares of company stock worth $2,323,150. Insiders own 1.27% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds have recently bought and sold shares of the company. FSA Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $30,000. Prospera Private Wealth LLC bought a new position in Edwards Lifesciences in the third quarter valued at approximately $32,000. Avior Wealth Management LLC boosted its holdings in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares during the period. HHM Wealth Advisors LLC bought a new stake in shares of Edwards Lifesciences during the second quarter worth $55,000. Finally, Peoples Bank KS acquired a new stake in shares of Edwards Lifesciences during the third quarter worth $40,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.